POWERING A NEW ENGINE FOR EARLY-STAGE DRUG DISCOVERY & DEVELOPMENT

January 2021 Corporate Overview
Academia: A Primary Source of Innovation in Medicine
Drivers of Innovation in Medicine

Academic laboratories are a prime source of new, scientifically innovative therapies for patients

Drug discoveries from universities account for:

- 31% of scientifically innovative (or first-in-class) medicines
- 30% of new drugs addressing unmet medical needs
- 25% of new therapeutic biologics
Pharma companies and biotech investors tend to license/invest at later stages of drug discovery

Basic Research
- Target identification
- Pathway elucidation

Target validation
- HTS, tool compounds
- Hit compounds

Lead identification
- Lead optimization
- Toxicity studies

IND enabling

Clinical Development

12-18 mos from clinic

Traditional Pharma and Investor $
Autobahn invests earlier, de-risking projects and advancing new ideas

Autobahn Labs’ mission is to address the key financing and expertise gaps to realize the potential of novel science to create transformative therapies.
Autobahn’s Model: Up to $5M in direct investment to translate academic research into a preclinical development candidate.
Autobahn brings intellectual, physical, and financial capital to projects

**Intellectual Capital**

**OPERATIONAL EXPERTISE**

Team includes industry experts with extensive experience in strategy, R&D, and science to execute and manage each Seed Co.

Integrated workplan increases efficiency and reduces time.

**Physical Capital**

**DRUG DISCOVERY**

Industrialized drug discovery capabilities to drive new medicines forward.

Established framework and process with a strong record of delivering novel drug candidates.

**Financial Capital**

**INVESTOR VISION**

Willing to invest up to $5M seed money to advance ProgramCos to preclinical drug candidates and secure IP.

Long-term commitment for follow-on investment.
Evotec’s deep drug discovery expertise and infrastructure available to all Autobahn-backed projects

EVOTEC SERVICES ARE PROVIDED AT COST, DRIVING SIGNIFICANT SAVINGS TO EACH PROGRAM

INTEGRATED DRUG DISCOVERY PLAN WITH CLEAR GO / NO-GO DECISIONS DEVELOPED AT OUTSET

Single point of contact at Autobahn | Access to more than 3,400 scientists | 50% with PhDs
Evotec’s proven track record of success

40+ Preclinical candidates nominated

>300 clinical patents covering all major therapeutic areas

25 compounds approved for clinical trials
Forging close partnerships with universities

Powering a new engine for early-stage drug discovery and development

1. Master Agreement
   - Agreement between University and Autobahn Labs establishes overall relationship, program selection, company creation, and pre-defined economic terms
   - Each opportunity / program is a separate company under the umbrella agreement

2. Identify Potential Programs
   - Joint effort between Autobahn Labs and University to identify faculty and programs of potential interest
   - Autobahn conducts deep scientific, clinical, and commercial diligence
   - Mutual agreement to work together; collaborative effort to define program plan, milestones, and budget

3. Create new company & execute plan
   - Autobahn Labs sets up jointly-owned company and invests up to $5M in staged funding
   - De-risk the program and create new IP and value
   - Goal is to reach a Preclinical Development Candidate (PDC)
Identifying Novel Science: Program Selection Criteria

Scientific Merit
- Novel science
- Druggability of target/pathway
- Level of target/pathway validation
- Probability of technical success

Development Potential
- Evaluation of clinical & regulatory pathways
- Fast path to clinical Proof-of-Concept
- Attractive Target Product Profile

Opportunity For Impact
- Unmet medical need
- Competitive landscape
- Degree of differentiation
- Potential for partnering
- Intellectual Property
Areas of Interest

In Scope

• Drug discovery programs
  • Target-centered hypotheses
  • Phenotypic screens
  • Potential development candidates
  • Computationally-enabled programs

• Therapeutic area agnostic
  • Requires path to early clinical proof-of-concept/mechanism

• Modality agnostic
  • Small molecule, biologic, cell & gene therapy, oligonucleotides

Out of Scope

• Research reagents, animal models, assays, tools, cell lines

• Biomarker development (without a specific therapeutics proposal)

• Repurposing, reformulation, or “me-toos”

• Startups
The Autobahn Difference

Vested partnerships with academic institutions and scientists

Deep operational expertise provided by industry experts, 3,000+ scientists

Industrialized drug discovery capabilities

Long-term capital and committed investors

Established drug discovery framework with track record of advancing discovery and preclinical research
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. The company operates worldwide providing the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic.

Samsara BioCapital is a leading life science venture fund focused on creating outstanding companies to advance innovative therapies to patients in need. Samsara’s business model supports ongoing strategic investments, allowing the organization to make committed, long-term investments in promising new areas of medicine.

KCK, Ltd. is a single-family, evergreen fund that invests across a broad range of sectors and in companies of all stages in the US, Europe and Emerging Markets. Investments are flexible and long-term, with a unique focus on technically and scientifically challenging projects.
Autobahn’s team of experts create an integrated workplan to accelerate the development of academic innovation.
Autobahn Labs Credo

We believe:

In the power of ideas to transform medicine.

In investing in the best people and the best science – committed and passionate academic partners and scientists, novel research.

In committed, long-term partnerships, and the ability to achieve together.

That well-planned ideas can thrive through operational scale and capital efficiencies.

That no disease or modality should go overlooked.

Together, we can power a new engine for early-stage drug discovery and deliver meaningful new therapies for patients.
Together, we can catalyze the translation of novel science to transformative therapies